Lotilaner ophthalmic solution, 0.25% + Vehicle control
ApprovedCompleted 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Demodex Blepharitis
Conditions
Demodex Blepharitis
Trial Timeline
Dec 27, 2023 → Jan 27, 2025
NCT ID
NCT06182358About Lotilaner ophthalmic solution, 0.25% + Vehicle control
Lotilaner ophthalmic solution, 0.25% + Vehicle control is a approved stage product being developed by Tarsus Pharmaceuticals for Demodex Blepharitis. The current trial status is completed. This product is registered under clinical trial identifier NCT06182358. Target conditions include Demodex Blepharitis.
Hype Score Breakdown
Clinical
20
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06182358 | Approved | Completed |
Competing Products
1 competing product in Demodex Blepharitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| GLK-321 low dose BID + GLK-321 mid dose BID + GLK-321 high dose BID + GLK-321 high dose QD + Placebo BID | Glaukos | Phase 2 | 39 |